Cancer clinical trials in the region Auvergne-Rhône-Alpes
478 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Endometrial cancer
#NCT07044336
#2024-518777-34-00
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
AstraZeneca
Phase 3
Prostate cancer
#NCT06136650
#2023-504957-11-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Internal Vectorised Radiotherapy (IVR)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Internal Vectorised Radiotherapy (IVR)
5 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Lymphoma
CLL & Richter's syndrome
#NCT05254743
#2023-507699-38-00
Required histologic types
B cell lymphoma
CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required genetic anomalies
Other mutation
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
10 recruiting sites
Loxo Oncology
Phase 3
Lymphoma
#NCT06284122
#2023-505436-35-00
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma
Required renal function statuses
30-50 ml/min
< 30 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Allogeneic stem cell transplant
Radiotherapy
37 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 3
Kidney cancer
#NCT07227402
#2024-517136-21-00
Required histologic types
Clear cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Immunotherapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
11 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT07318558
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required disease stage
Localized
Required HRD statuses
HRD Negative
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Required previous treatments at advanced or metastatic stage
Chemotherapy
5 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Stomach and esophageal cancer
#NCT06901531
#2024-519773-19-00
Required histologic types
Stomach
Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
Claudin 18.2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 5)
CPS Positive (5 <= X < 10)
CPS Positive (X >= 10)
Excluded genetic anomalies
HER2
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
17 recruiting sites
Astellas Pharma Développement mondial, Inc.
Phase 3
Multiple myeloma
#NCT05519085
#2023-509859-13-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
10 recruiting sites
Celgene
Phase 3
Multiple myeloma
#NCT06615479
#2024-515279-37-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Monoclonal antibodies
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
Multiple myeloma
#NCT05552222
#2022-000909-28
Required histologic types
Symptomatic multiple myeloma
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
9 recruiting sites
Janssen